Epidemiology of Campylobacter jejuni Isolated from Patients with Guillain-Barré and Fisher Syndromes in Japan

Masaki Takahashi,¹ Michiaki Koga,² Keiko Yokoyama,¹ and Nobuhiro Yuki²*

Department of Microbiology, Tokyo Metropolitan Institute of Public Health, Tokyo,¹ and Department of Neurology, Dokkyo University School of Medicine, Tochigi,² Japan

Received 7 May 2004/Returned for modification 17 August 2004/Accepted 8 September 2004

Campylobacter jejuni isolation is the standard for the diagnosis of this type of bacterial infection, but there have been no epidemiological studies of a large number of C. jejuni isolates from patients with Guillain-Barré syndrome (GBS) and Fisher syndrome (FS). For 13 years, stool specimens from GBS/FS patients have been sent from 378 hospitals throughout Japan to the Tokyo Metropolitan Institute of Public Health. A total of 113 strains (11%) were isolated from the stool specimens from 1,049 patients. The isolation rate did not differ by region. The rates were 22% for 449 patients with a history of diarrhea and 2% for the others. An additional 18 isolates were provided by various hospitals. There was no noticeable seasonal distribution in the onset of C. jejuni isolated from patients with GBS/FS. The male/female ratios were 1.7:1 for GBS and 2.2:1 for FS. The patient age range showed a peak in 10- to 30-year-old subjects who had GBS and in 10- to 20-year-old subjects who had FS. The predominance of young adults and male patients who had C. jejuni-associated GBS/FS may be related to the preponderance of young adults and male patients who had C. jejuni enteritis. The median interval from diarrhea onset to neurologic symptom onset was 10 days for GBS/FS. Penner’s C. jejuni serotype HS:19 was more frequently present in GBS (67%) than in enteritis (6%) patients. HS:2 was more frequent in FS (41%) than in enteritis (14%) patients. These findings suggest that certain C. jejuni strains specifically trigger GBS and that others specifically trigger FS.

Guillain-Barré syndrome (GBS), the prototype of postinfectious autoimmune diseases, is characterized by acute onset of limb weakness and loss of tendon reflexes. Since the near elimination of poliomyelitis worldwide, GBS is the most frequent cause of acute flaccid paralysis, the mean annual incidence being 1.3 cases per 100,000 population (11). Fisher syndrome (FS) is characterized by acute onset of ophthalmoplegia, ataxia, and areflexia. It is considered a variant of GBS, ataxia, and areflexia. It is considered a variant of GBS.

Serological studies are important for understanding the epidemiology of C. jejuni-associated GBS/FS, but there are no recommended methodologies as to the antigens to be used or the standards of judgment. A comparative study made in Japan recommended methodologies as to the antigens to be used or the standards of judgment. A comparative study made in Japan recommended methodologies as to the antigens to be used or the standards of judgment.
ported in 95% of 102 GBS patients and in 93% of 29 FS patients. The median latent period between antecedent symptoms and neuropathy onset was 10 days for both groups; within 2 weeks in most cases (Fig. 5). Gastrointestinal symptoms were most frequent in cases of GBS (90%) and FS (79%), often being accompanied by fever. Six (5%) patients with GBS/FS had a history of upper respiratory tract infectious symptoms only, and three (2%) had experienced only preceding fever. Anti-ganglioside IgG antibodies in serum were tested during the acute phase of illness in 120 of 131 patients (Table 2). Most patients had some antibodies; anti-GM1 and anti-GD1a IgG antibodies were frequent in GBS and anti-GQ1b IgG antibody in FS.

**Serogroups of *C. jejuni* isolates.** HS:19 was more frequently isolated from GBS patients than from enteritis patients. The HS:2 and HS:4 complexes were isolated more frequently from FS patients than from enteritis patients. None of the GBS and FS isolates were HS:41.

**DISCUSSION**

Assessing the frequency of *C. jejuni* infection in GBS/FS patients is difficult since it depends on such varied factors as antecedent symptoms, the duration of convalescent excretion of the bacterium, and the kinds of antibiotics administered. Thus, few surveillance studies have included large numbers of patients. Kuroki et al. (17) reported that 30% of 46 GBS patients in the Kinki district of Japan had positive stool cultures. In a subsequent study, these authors isolated 13 strains (17%) of *C. jejuni* from 76 patients (9). In contrast, 8% of 103 patients had positive cultures in England (25), and 9% of 138 patients had positive cultures in The Netherlands (28). The isolation rate was 11% in the present study, which does not differ significantly from European values.

The latent period between intestinal infection and the onset of GBS/FS often exceeds the duration of convalescence excretion of the bacterium. GBS/FS patients therefore frequently have negative stool cultures. Kuroki’s group (9) reported that all 13 positive stool specimens were obtained within 10 days after onset of GBS symptoms, and 9 of the 13 specimens were obtained within 5 days. We could isolate *C. jejuni* from stool specimens obtained more than 1 month after the onset of GBS (the 35th day) or FS (the 40th day). This finding is not excep-

### RESULTS

#### Culture results.

We obtained stool specimens from 1,049 patients with GBS (n = 763) or FS (n = 286). The median interval between neuropathy onset and stool sampling was 13 days (range, 1 to 150 days). Gastrointestinal symptoms occurred in 449 (43%) patients; upper respiratory symptoms occurred in 503 (48%) patients. A total of 113 *C. jejuni* strains (GBS, 87; FS, 26) (11%) were isolated from the 1,049 patients, although at least 11 patients had been treated with antibiotics. The combined isolation rate, 11% (GBS, 11%; FS, 9%), did not differ by region (Fig. 1). The rate was 22% for the 449 patients with a history of diarrhea and 2% for the remaining patients.

#### Characteristics of *C. jejuni*-positive patients.

The seasonal distribution (Fig. 3) is lower in October and November. *C. jejuni*-associated GBS showed a peak in 10- to 30-year-olds (Fig. 4). *C. jejuni*-associated FS demonstrated a peak in 10- to 20-year-olds. Males predominated for both GBS (male/female ratio, 1.7:1) and FS (2.2:1).

Antecedent symptoms in culture-positive patients were recorded in 95% of 102 GBS patients and in 93% of 29 FS patients. The median latent period between antecedent symptoms and neuropathy onset was 10 days for both groups; within 2 weeks in most cases (Fig. 5). Gastrointestinal symptoms were most frequent in cases of GBS (90%) and FS (79%), often being accompanied by fever. Six (5%) patients with GBS/FS had a history of upper respiratory tract infectious symptoms only, and three (2%) had experienced only preceding fever. Anti-ganglioside IgG antibodies in serum were tested during the acute phase of illness in 120 of 131 patients (Table 2). Most patients had some antibodies; anti-GM1 and anti-GD1a IgG antibodies were frequent in GBS and anti-GQ1b IgG antibody in FS.

#### Serogroups of *C. jejuni* isolates.

HS:19 was more frequently isolated from GBS patients than from enteritis patients. The HS:2 and HS:4 complexes were isolated more frequently from FS patients than from enteritis patients. None of the GBS and FS isolates were HS:41.

### DISCUSSION

Assessing the frequency of *C. jejuni* infection in GBS/FS patients is difficult since it depends on such varied factors as antecedent symptoms, the duration of convalescent excretion of the bacterium, and the kinds of antibiotics administered. Thus, few surveillance studies have included large numbers of patients. Kuroki et al. (17) reported that 30% of 46 GBS patients in the Kinki district of Japan had positive stool cultures. In a subsequent study, these authors isolated 13 strains (17%) of *C. jejuni* from 76 patients (9). In contrast, 8% of 103 patients had positive cultures in England (25), and 9% of 138 patients had positive cultures in The Netherlands (28). The isolation rate was 11% in the present study, which does not differ significantly from European values.

The latent period between intestinal infection and the onset of GBS/FS often exceeds the duration of convalescence excretion of the bacterium. GBS/FS patients therefore frequently have negative stool cultures. Kuroki’s group (9) reported that all 13 positive stool specimens were obtained within 10 days after onset of GBS symptoms, and 9 of the 13 specimens were obtained within 5 days. We could isolate *C. jejuni* from stool specimens obtained more than 1 month after the onset of GBS (the 35th day) or FS (the 40th day). This finding is not excep-

### TABLE 1. Isolation rate of *C. jejuni* and antecedent illness in patients with GBS and FS

<table>
<thead>
<tr>
<th>Antecedent symptoms</th>
<th>GBS (%)</th>
<th>FS (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>GI only</td>
<td>255</td>
<td>49</td>
</tr>
<tr>
<td>GI plus URTI</td>
<td>107</td>
<td>38</td>
</tr>
<tr>
<td>URTI only</td>
<td>209</td>
<td>149</td>
</tr>
<tr>
<td>Fever only</td>
<td>42</td>
<td>10</td>
</tr>
<tr>
<td>Others</td>
<td>25</td>
<td>5</td>
</tr>
<tr>
<td>None</td>
<td>121</td>
<td>31</td>
</tr>
<tr>
<td>Total</td>
<td>759</td>
<td>282</td>
</tr>
</tbody>
</table>

* GI, gastrointestinal infection; URTI, upper respiratory tract infection.

* Eight cases were excluded because detailed information was not available.
tional because in some cases the excretion of C. jejuni in stools has continued for 6 to 9 weeks (14, 30).

There is no clear seasonal distribution of GBS in Western countries (11), whereas in northern China GBS peaks in late summer, which may be due to the high frequency of C. jejuni infection (10). In a previous study done in the Kinki district of Japan, the seasonal distribution of C. jejuni-associated GBS peaked in March, an autumn occurrence was relatively infrequent, and there was no seasonal difference found for the group of GBS patients without C. jejuni infection (9). We also detected no seasonal predominance. Autumn occurrences were relatively infrequent. Although the seasonality of C. jejuni enteritis in Japan is less pronounced than in other developed countries, which show a seasonal distribution with a well-defined summer peak (26), the incidence of C. jejuni enteritis tends to be higher from April to July (21).

In North America and Europe, a bimodal age distribution has been reported for GBS, with peaks at 20 to 40 years and 60 to 70 years (2, 13). Males are more commonly affected by GBS than females (~1.25:1) (11). In England the male/female ratio was 3.5:1 in the C. jejuni-seropositive group, whereas it was 1.5:1 in the C. jejuni-seronegative group (25). C. jejuni-associated GBS in northern China occurs mainly among children and young adults (10), the male/female ratio being 1.2:1 in C. jejuni-seropositive GBS patients and 0.8:1 in C. jejuni-seronegative patients. In the Kinki district of Japan, the age distribution showed a peak between 10 and 30 years (9). The male/female ratio was 2.4:1 for GBS patients who had had C. jejuni infection and 2.2:1 for the other GBS patients. In the present study, the age distribution showed a peak between 10 and 30 years for GBS and between 10 and 20 years for FS. A majority of male patients had both GBS and FS, the respective male/female ratios being 1.7:1 and 2.2:1. In English patients suffering from gastrointestinal symptoms, the highest C. jejuni isolation rates were for young adults, males predominating in the 15 to 24 years (1.7:1) and 45 to 54 years (1.6:1) age groups (26). The dominance of young adult and male patients among those with C. jejuni infection may therefore partly explain the findings for C. jejuni-associated GBS/FS. In England, the median interval between the onset of diarrhea and neuropathic symptoms was 9 days (range, 2 to 20) for 19 GBS patients (25). In our study, the median interval was 10 days (range, 1 to 24) for 115 GBS/FS patients.
Penner’s serotyping system is a useful phenotyping technique for C. jejuni and C. coli (24). The system can divide C. jejuni and C. coli into about 60 types. C. jejuni has been isolated from patients’ stools at GBS onset. A large number of Penner serotypes have been reported in the literature: HS:1, HS:2, HS:4, HS:5, HS:10, HS:13/65, HS:16, HS:19, HS:23, HS:35, HS:37, HS:41, HS:44, and HS:64 (5), but Kuroki’s group showed that 75% of 16 isolates from GBS patients were HS:19 and that 1 of 2 isolates from FS patients was HS:2 (22). Elsewhere we reported that in Japan HS:19 strains are significantly over-represented in GBS patients, accounting for 52% of 31 isolates from GBS patients but only 5% of 215 control isolates (34). HS:2 was found to be over-represented in FS patients (present in 71% of the patients versus 38% of the controls), but only 7 isolates from FS patients were studied. In South Africa, 6 of 9 GBS isolates were HS:41; this serotype accounts for only 0.1% of enteritis strains (8). In contrast, in The Netherlands and Belgium only two isolates from 12 GBS patients were HS:19, and none were HS:41 (5). Only one isolate from four FS patients was HS:2 (5). Our study confirms that GBS is significantly associated with HS:19 and that statistically FS is associated with HS:2. None of our C. jejuni isolates from GBS patients were HS:41. These findings are a strong indication that certain C. jejuni strains trigger the development of GBS, others the development of FS.

HS:19 strains, whether isolated from GBS patients or enteritis patients without neurological involvement, were related clonally (7, 19, 22), whereas clonality was lacking for other serotypes associated with GBS (5, 6). The hypothesis that a “bad bug causes GBS/FS” cannot be dismissed. The methods used may simply lack the power to detect particular C. jejuni strain determinants related to GBS/FS. There is cumulative evidence of molecular mimicry between human gangliosides and that the C. jejuni lipo-oligosaccharide (LOS) causes GBS/FS (31). Anti-GM1 and anti-GD1a IgG antibodies have been detected in patients who developed GBS subsequent to C. jejuni enteritis. Sensitization with a GM1-like LOS, as well as with GM1 ganglioside, has produced an animal model of GBS (32, 36). Analysis of the genes involved in the synthesis of ganglioside-like LOS may be of great importance for clarifying which C. jejuni strains involved in the pathogenesis of GBS/FS. The presence of LOS synthesis genes (cst-II, cgtA, and cgtB) is associated statistically with GBS-related isolates (20). GQ1b ganglioside is a target molecule for IgG antibody in FS (3), and all C. jejuni strains studied that bore the GQ1b epitope had cst-II, an essential gene for production of GQ1b-like LOS (27). Whether these genes are present in our GBS/FS isolates needs to be investigated, as well as whether their presence is more frequent than in the enteritis controls.

TABLE 2. Anti-ganglioside antibodies in patients with GBS and FS from whom C. jejuni was isolated

<table>
<thead>
<tr>
<th>IgG antibody</th>
<th>No. of patients (%) with:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>GBS (n = 92)</td>
</tr>
<tr>
<td>Anti-GM1</td>
<td>68 (74)</td>
</tr>
<tr>
<td>Anti-GD1a</td>
<td>45 (49)</td>
</tr>
<tr>
<td>Anti-GQ1b</td>
<td>3 (3)</td>
</tr>
</tbody>
</table>

TABLE 3. Penner serogroup of isolates from GBS and FS and uncomplicated enteritis

<table>
<thead>
<tr>
<th>Penner serogroup</th>
<th>Serotype(s)</th>
<th>No. of C. jejuni isolates (% from:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>GBS (n = 102)^a</td>
</tr>
<tr>
<td>A 1, 44</td>
<td>5 (5)</td>
<td>0</td>
</tr>
<tr>
<td>B 2</td>
<td>6 (6)</td>
<td>12 (41)</td>
</tr>
<tr>
<td>C 3</td>
<td>1 (1)</td>
<td>1 (3)</td>
</tr>
<tr>
<td>D 4, 13, 16, 43, 50</td>
<td>8 (8)</td>
<td>11 (38)</td>
</tr>
<tr>
<td>E 5</td>
<td>2 (2)</td>
<td>0</td>
</tr>
<tr>
<td>F 6, 7</td>
<td>1 (1)</td>
<td>1 (3)</td>
</tr>
<tr>
<td>G 8</td>
<td>3 (3)</td>
<td>0</td>
</tr>
<tr>
<td>O 19</td>
<td>68 (67)^b</td>
<td>1 (3)</td>
</tr>
<tr>
<td>U 31</td>
<td>0</td>
<td>1 (3)</td>
</tr>
<tr>
<td>Y 37</td>
<td>3 (3)</td>
<td>0</td>
</tr>
<tr>
<td>Z 38</td>
<td>0</td>
<td>1 (3)</td>
</tr>
<tr>
<td>Untypeable</td>
<td>8 (8)</td>
<td>1 (3)</td>
</tr>
</tbody>
</table>

^a Two strains were serotyped as A/G or O/Y serogroups.
^b P < 0.001 (compared to the enteritis isolates; odds ratio [OR], 30.6; 95% confidence interval [CI], 17.5 to 52.4).
^c P < 0.001 (compared to the enteritis isolates; OR, 4.2; 95% CI, 1.9 to 9.1).
^d P < 0.001 (compared to the enteritis isolates; OR, 4.3; 95% CI, 1.9 to 9.5).

ACKNOWLEDGMENTS

This study was supported in part by grants-in-aid from the Ichiro Kanehara Foundation, by the Kanae Foundation for Life & SocioMedical Science, by the Japan Intractable Diseases Research Foundation, by a grant for Scientific Research (B) (KAKENHI 14370210) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan, by a Research Grant for Neuroimmunological Diseases from the Ministry of Health, Labour, and Welfare of Japan, by a Health Sciences Research Grant (Research on Psychiatric and Neurological Diseases and Mental Health) from the Ministry of Health, Labour, and Welfare of Japan, and by a grant from the Human Frontier Science Program (RGP 38/2003).

We thank the Division of Clinical Microbiology of the Tokyo Metropolitan Hospitals (Komagome and Bokutoh) for the isolation of the sporadic enteritis strains.

REFERENCES

Page 43, 2005
C. JEJUNI INFECTIONS AND GUILLAIN-BARRÉ SYNDROME


